Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
